The Biologics News and Reports Portal

Show Cart

Target Pipelines

Results 51 - 60 of 67

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

250.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

500.00 €

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

300.00 €

Feb 2016 Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

200.00 €

Jul 2015 Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

400.00 €

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Featured Products

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Target Pipelines

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

Apr 2016 Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Feb 2016 Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Jul 2015 Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Feb 2015 Competitor Analysis: Specific and Bispecific Her3 Antibodies

Jul 2013 Competitor Analysis ErbB / Her Receptor Antagonists

Jul 2013 Competitor Analysis: c-MET/HGF Inhibitors

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing